日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Post hoc exploratory analysis of the effect of foslevodopa/foscarbidopa continuous subcutaneous infusion on nocturia in patients with Parkinson's disease

对帕金森病患者持续皮下输注磷酸左旋多巴/磷酸卡比多巴对夜尿症影响的事后探索性分析

Chaudhuri, K Ray; Bouchard, Manon; Freire-Alvarez, Eric; Pahwa, Rajesh; Bergmann, Lars; Gupta, Resmi; Kukreja, Pavnit; Shah, Megha B; Isaacson, Stuart H

Dyskinesia and Pain in Advanced Parkinson's Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study

晚期帕金森病患者的运动障碍和疼痛:来自 3b 期开放标签随机 DYSCOVER 研究的事后分析

Freire-Alvarez, Eric; Vanni, Paola; Kurča, Egon; Lopez-Manzanares, Lydia; Kovács, Norbert; Spanaki, Cleanthe; Gao, Tianming; Bergmann, Lars; Sánchez-Soliño, Olga

Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance

持续皮下注射磷酸左旋多巴/磷酸卡比多巴治疗帕金森病运动波动:启动和维持治疗的注意事项

Fung, Victor S C; Aldred, Jason; Arroyo, Martha P; Bergquist, Filip; Boon, Agnita J W; Bouchard, Manon; Bray, Sarah; Dhanani, Sara; Facheris, Maurizio F; Fisseha, Nahome; Freire-Alvarez, Eric; Hauser, Robert A; Jeong, Anna; Jia, Jia; Kukreja, Pavnit; Soileau, Michael J; Spiegel, Amy M; Talapala, Saritha; Tarakad, Arjun; Urrea-Mendoza, Enrique; Zamudio, Jorge; Pahwa, Rajesh

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

帕金森病患者持续皮下注射左旋多巴/磷酸卡比多巴:一项为期12个月的单臂、开放标签3期研究的安全性和有效性结果

Aldred, Jason; Freire-Alvarez, Eric; Amelin, Alexander V; Antonini, Angelo; Bergmans, Bruno; Bergquist, Filip; Bouchard, Manon; Budur, Kumar; Carroll, Camille; Chaudhuri, K Ray; Criswell, Susan R; Danielsen, Erik H; Gandor, Florin; Jia, Jia; Kimber, Thomas E; Mochizuki, Hideki; Robieson, Weining Z; Spiegel, Amy M; Standaert, David G; Talapala, Saritha; Facheris, Maurizio F; Fung, Victor S C

Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

更正:帕金森病患者持续皮下注射左旋多巴/磷酸卡比多巴:一项为期 12 个月的单臂、开放标签 3 期研究的安全性和有效性结果

Aldred, Jason; Freire-Alvarez, Eric; Amelin, Alexander V; Antonini, Angelo; Bergmans, Bruno; Bergquist, Filip; Bouchard, Manon; Budur, Kumar; Carroll, Camille; Chaudhuri, K Ray; Criswell, Susan R; Danielsen, Erik H; Gandor, Florin; Jia, Jia; Kimber, Thomas E; Mochizuki, Hideki; Robieson, Weining Z; Spiegel, Amy M; Standaert, David G; Talapala, Saritha; Facheris, Maurizio F; Fung, Victor S C

Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial

一项随机试验表明,左旋多巴-卡比多巴肠溶凝胶可减轻帕金森病患者的运动障碍。

Freire-Alvarez, Eric; Kurča, Egon; Lopez Manzanares, Lydia; Pekkonen, Eero; Spanaki, Cleanthe; Vanni, Paola; Liu, Yang; Sánchez-Soliño, Olga; Barbato, Luigi M